The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data.
The EV maker expects construction to be completed by 2026 and sees key suppliers locating in the park, reducing shipping, logistics, and warehousing costs.
The Finchat-compiled consensus estimates call for adjusted earnings per share of $0.93and revenue of $7.12 billion for the first quarter of the fiscal year 2025.
Investment firm Stifel said the deal "represents a pathway to value realization for similarly tariff-impacted businesses with solid franchises and attractive valuation."
ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).
The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August.
Skechers shareholders can elect to receive $63 per share in cash or $57 per share in cash and one unlisted, non-transferable equity unit (LLC unit) in a newly formed, privately held firm that will be the parent company of Skechers.
The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million.
BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.
According to a Reuters report, Chevron CFO Eimear Bonner said share repurchases in 2025 could be between $11.5 billion and $13 billion, which would be at the lower end of the company's guidance of $10 billion to $20 billion.
The company said it remains confident in its strategy and continues to see a path to achieving positive operating income in 2026, despite the uncertainties.
